We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Toolkit Developed for Iron Deficiency in Pregnancy

By LabMedica International staff writers
Posted on 04 Sep 2019
Print article
Image: A peripheral blood smear from a patient with iron deficiency anemia: significant hypochromia and microcytosis is seen, as well as moderate variation in size and shape of the red cells (Photo courtesy of American Society of Hematology).
Image: A peripheral blood smear from a patient with iron deficiency anemia: significant hypochromia and microcytosis is seen, as well as moderate variation in size and shape of the red cells (Photo courtesy of American Society of Hematology).
The risk of iron deficiency (ID) increases during pregnancy due to an increase in maternal iron requirements to accommodate the expansion of maternal red blood cell (RBC) mass, development of the placenta and fetus, and the loss of blood associated with labor and delivery.

Fortunately, early detection of ID and treatment with daily iron supplementation is a straightforward and effective method of addressing ID. Iron deficiency and ID anemia (IDA) can be detected using simple blood tests of hemoglobin and ferritin, but often go unrecognized and untreated due to lack of knowledge of their implications and competing clinical priorities.

A team of scientists working with St. Michael’s Hospital (Toronto, ON, Canada) developed and implemented a novel quality-improvement toolkit: ID in pregnancy with maternal iron optimization (IRON MOM) at the hospital. The toolkit included clinical pathways for diagnosis and management, educational resources for clinicians and patients, templated laboratory requisitions, and standardized oral iron prescriptions.

To measure the effectiveness of the toolkit, the team included the rates of ferritin testing, and outcome measures of the proportion of women with an antenatal hemoglobin value below 100 g/L (anemia), the proportion of women who received a red blood cell (RBC) transfusion during pregnancy, and the proportion of women who received an RBC transfusion immediately following delivery or in the 8-week postpartum period.

The pre-intervention period was from January 2012 to December 2016, and the post-intervention period was from January 2017 to December 2017. From the electronic patient records (EPR), 1,292 and 2,400 ferritin tests and 16,603 and 3,282 antenatal hemoglobin results were extracted pre- and post-intervention, respectively. One year after implementation of IRON MOM, they found a 10-fold increase in the rate of ferritin testing in the obstetric clinics at the hospital and a lower risk of antenatal hemoglobin values below 100 g/L (pre-intervention 13.5%; post-intervention 10.6%). In addition, a significantly lower proportion of women received an RBC transfusion during their pregnancy (1.2% pre-intervention versus 0.8% post-intervention) or immediately following delivery and in the eight weeks following (2.3% pre-intervention versus 1.6% post-intervention).

The authors concluded that the introduction of a standardized toolkit including diagnostic and management pathways as well as other aids increased ferritin testing and decreased the incidence of anemia among women presenting for delivery at their site. This strategy also resulted in reduced proportions of women receiving RBC transfusion during pregnancy and in the first eight weeks postpartum. The IRON MOM toolkit is a low-tech strategy that could be easily scaled to other settings.

Related Links:
St. Michael’s Hospital

New
Gold Member
Human Chorionic Gonadotropin Test
hCG Quantitative - R012
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Calprotectin Assay
Fecal Calprotectin ELISA
New
Ultra-Low Temperature Freezer
iUF118-GX

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Molecular Diagnostics

view channel
Image: The advanced molecular test is designed to improve diagnosis of a genetic form of COPD (Photo courtesy of National Jewish Health)

Groundbreaking Molecular Diagnostic Test Accurately Diagnoses Major Genetic Cause of COPD

Chronic obstructive pulmonary disease (COPD) and Alpha-1 Antitrypsin Deficiency (AATD) are both conditions that can cause breathing difficulties, but they differ in their origins and inheritance.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.